|
|
|
|
|
|||||||
|
Session 10
Oral Abstract Session
Late Breakers I Monday, 2 - 4 pm 6E |
| Moderators | Constance Benson, Univ. of Colorado Hlth. Sci. Ctr., Denver and Mario Stevenson, Univ. of Massachusetts Med. Ctr.,
Worcester | ||
| 2:00 LB1. | Molecular Characterization of a Novel Simian Immunodeficiency Virus with a Vpu Gene from Greater Spot-Nosed Monkeys (Cercopithecus nictitans) from Cameroon V. Courgnaud*1, M. Salemi2, X. Pourrut1, E. Mpoudi-Ngole3, B. Abela3, P. Auzel3, F. Bibollet-Ruche4, B. Hahn4, A. M. Vandamme2, E. Delaporte1, and M. Peeters1 1UR36, Inst. de Recherche pour le Développement (IRD) and Univ. of Montpellier I, France; 2Rega Inst. for Med. Res., KU Leuven, Belgium; 3Projet PRESICA, Hôp. Militaire, Yaounde, Cameroon; and 4Univ. of Alabama at Birmingham
| ||
| 2:15 LB2. | Relationship between the Menstrual Cycle and the Daily Pattern of HIV-1 RNA Shedding in the Genital Tract of HIV-1-Infected Women S. Benki*1,2, S. B. Mostad2, B. A. Richardson2, K. Mandaliya3, J. K. Kreiss2, and J. Overbaugh1 1Fred Hutchinson Cancer Res. Ctr., Seattle, WA; 2Univ. of Washington, Seattle; and 3Coast Provincial Gen. Hosp., Mombasa, Kenya
| ||
| 2:30 LB3. | Determination of Virus Burst Size in Vivo Using a Single-Cycle SIV in Rhesus Macaques H. Yuan Chen*1,2, M. Di Mascio3, A. Perelson3, A. Gettie1,4, D. Ho1,5, L. Zhang1, and 1>Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY; 2New York Univ., NY; 3Los Alamos Natl. Lab., NM; and 4Tulane Regional Primate Res. Ctrl, Covington, LA; and 5Rockefeller Univ., New York, NY
| ||
| 2:45 LB4. | A Novel Adenoviral Vaccine Based on a Chimpanzee Derived Isolate as a Vaccine Carrier for HIV-1 gag J. Fitzgerald1, G.-P. Gao2, J. Wilson2, and H. C. J. Ertl*1 1Wistar Inst., Philadelphia, PA and 2Univ. of Pennsylvania, Philadelphia
| ||
| 3:00 LB5. | Rapid Evolution of the Neutralizing Antibody Response following Primary HIV Infection D. D. Richman*1, T. Wrin2, S. Little1, and C. Petropoulos2 1VA San Diego Healthcare System and Univ. of California, San Diego and 2ViroLogic, Inc., South San Francisco, CA
| ||
| 3:15 LB6. | HIV-1-Specific CD8+ T-Cell Responses Contribute to the Differential HIV Disease Progression in HIV-1-Infected Individuals with Variable HLA-B35 Genotype X. Jin*1, X. Gao2, M. Ramanathan, Jr.3, G. R. Deschenes3, G. Nelson2, S. J. O’Brien4, D. D. Ho3, T. R. O’Brien5, and M. Carrington2 1Univ. of Rochester Med. Ctr., NY; 2SAIC, NCI, Frederick, MD; 3Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY; 4NCI, NIH, Frederick, MD; and 5NCI, NIH Rockville, MD
| ||
| 3:30 LB7. | HIV Preferentially Infects HIV-Specific CD4 T Cells D. Douek*1, J. Brenchley1, M. Betts1, D. Ambrozak1, B. Hill1, Y. Okamoto1, J. Casazza2, J. Kuruppu1, K. Kunstman3, M. Dybul1, A. Oxenius4, D. Price4, M. Connors1, and R. Koup1 1NIAID, NIH, Bethesda, MD; 2Univ. of Texas Southwestern Med. Ctr., Dallas; 3Northwestern Univ. Med. Sch., Chicago, IL; and 4John Radcliffe Hosp., Oxford, UK
| ||
| 3:45 LB8. | CD4 T-Lymphocyte Recovery in Individuals with Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort Study G. Kaufmann*1, L. Perrin2, G. Pantaleo3, M. Opravil4, H. Furrer6 , A. Telenti3, B. Hirschel2, B. Ledergerber4, P. Vernazza7, E. Bernasconi8, M. Rickenbach3, M. Egger10, and M. Battegay1 1Basel Ctr. for HIV Res., Switzerland; 2Univ. Hosp. Geneva, Switzerland; 3 CHUV, Lausanne, Switzerland; 4Univ. Hosp. Zurich, Switzerland; 5Univ. Hosp. Berne, Switzerland; 7Cantonal Hosp. St.Gallen, Switzerland; 8Regional Hosp. Lugano, Switzerland; and 9Med. Res. Council Hlth. Services Res. Collaboration, Bristol, UK
|
